Magnetic hyperthermia ablation (MH) is a promising method for targeted drug delivery and cancer therapy. When exposed to an alternating magnetic field, magnetic nanoparticles produce localized heat, which permits tumor ablation and initiates the release of therapeutic medicines. By combining targeted medication release with hyperthermia-induced cell death, this dual-function strategy reduces systemic toxicity and adverse effects while increasing therapy efficacy. By providing better biocompatibility, extended circulation, and increased drug-loading capacity, the combination of lipid nanoparticles and magnetic nanoparticles has advanced the field even further. Overcoming biological barriers to effective delivery, guaranteeing uniform heat dispersion, and optimizing nanoparticle design are among the difficulties. Precision-targeting techniques and patient-specific nanoparticle compositions could transform drug delivery systems in personalized medicine.